Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing CD19-targeting CAR T-cell therapies for autoimmune diseases, and its news flow reflects this focus. Company updates frequently highlight progress with its lead autologous CAR T-cell therapy candidate, mivocabtagene autoleucel (miv-cel, KYV-101), in B-cell-driven autoimmune conditions.
Visitors to this KYTX news page can review announcements on Kyverna’s registrational trials in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). Recent press releases describe positive topline data from the KYSA-8 registrational Phase 2 trial in SPS and interim Phase 2 data from the KYSA-6 registrational Phase 2/3 trial in gMG, including reported effects on disability, mobility, and disease activity scores, as well as safety outcomes such as the absence of high-grade cytokine release syndrome or ICANS in the reported datasets.
News items also cover Kyverna’s broader development and financing activities. These include business updates and quarterly financial results, a loan facility with Oxford Finance LLC, and public equity offerings under an effective shelf registration statement on Form S-3. Additional releases describe investigator-initiated trials in multiple sclerosis and rheumatoid arthritis, Phase 1/2 trials in lupus nephritis, and the advancement of KYV-102, which the company characterizes as using a whole blood rapid manufacturing process.
Investors and followers of KYTX can use this page to track Kyverna’s press releases on clinical milestones, regulatory plans such as an anticipated BLA submission for SPS, corporate presentations at healthcare conferences, leadership and governance changes, and capital-raising transactions. Checking this feed provides a consolidated view of how the company reports its progress in autoimmune CAR T-cell therapy and related corporate developments.
Kyverna Therapeutics has co-authored a review with the National Institutes of Health on the application of CAR T-cell therapy for autoimmune diseases, published in Nature Reviews Immunology.
The review discusses the promising clinical outcomes of anti-CD19 CAR T cells in autoimmune patients, emphasizing optimal CAR construct design for safety and lasting immune reset.
Kyverna is recruiting for multiple trials using their candidate KYV-101 to treat myasthenia gravis, multiple sclerosis, and lupus nephritis.
With over 30 ongoing clinical trials, the review underscores the potential of CAR T-cell therapy in this field.
Kyverna Therapeutics will present data on the largest set of patients treated with KYV-101, an anti-CD19 CAR T-cell therapy, at EULAR 2024. The data covers 50 patients from more than 15 centers in the US and Europe, addressing 12 indications. Highlights include early efficacy and safety data, with a 12-month follow-up on a myasthenia gravis patient. The symposium, scheduled for June 14, will feature leading experts in rheumatology and neurology. Additionally, Kyverna will showcase preclinical development data for KYV-201 and proteomic markers associated with CAR T therapy response.
Kyverna Therapeutics (Nasdaq: KYTX) reported its Q1 2024 financial results, highlighting progress in autoimmune disease therapies. The company treated 30 patients by May 14, 2024, including those with myasthenia gravis, lupus nephritis, and multiple sclerosis. KYV-101, their CD19 CAR T-cell therapy, showed promising early clinical data and received Orphan Drug Designation for myasthenia gravis. Kyverna's balance sheet was strengthened by $366.9 million from their February IPO. However, the company reported a net loss of $26.7 million for Q1 2024, up from a $11.1 million loss in Q1 2023, with operating expenses increasing significantly.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.